Drug Trial Radar · NCT05276063
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Jul 1, 2022
Primary completion
Oct 15, 2024
Study completion Sep 26, 2025
Sponsor
- Lead sponsor
- Sling Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).
Conditions
- Thyroid Eye Disease
- Graves Orbitopathy
- Endocrine System Diseases
- Eye Diseases
- Thyroid Associated Ophthalmopathy
- Graves Ophthalmopathy
- Thyroid Diseases
- Orbital Diseases
- Proptosis
- IGF1R
- Exophthalmos
- Hashimoto
Interventions
LinsitinibDrug
Study medication taken twice daily by mouth
PlaceboDrug
Placebo taken twice daily by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Who Are Proptosis Responders at Week 24Time frame: 24 weeks
Locations
30 sites in 5 countries. Site status is shown where the registry gives one.
Thrive Health Research
Beverly Hills, California
UC San Diego Health
La Jolla, California
UCLA
Los Angeles, California
Byers Eye Institute - Stanford University
Palo Alto, California
Bascom Palmer Eye Institute
Miami, Florida
Center for Excellence in Eye Care
Miami, Florida
Sarasota Retina Institute
Sarasota, Florida
Chicago Oculofacial Plastic Surgery
Chicago, Illinois
Wolfe Eye Clinic
West Des Moines, Iowa
Mass Eye and Ear
Boston, Massachusetts
Kellogg Eye Center
Ann Arbor, Michigan
Kahana Oculoplastic & Orbital Surgery
Livonia, Michigan
Washington University in St. Louis/Barnes Jewish Hospital
Creve Coeur, Missouri
Columbia University
New York, New York
Wake Forest Baptist Health Eye Center
Winston-Salem, North Carolina
Oregon Health and Science University
Portland, Oregon
Neuro-Eye Clinical Trials, Inc.
Bellaire, Texas
Eyelid Center of Utah
Salt Lake City, Utah
West Virginia University Eye Institute
Morgantown, West Virginia
Toronto Retina Institute
North York, Canada
Vancouver Coastal Health Eye Care Center
Vancouver, British Columbia, Canada
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Endocrinology Pawilione Zonda
Milan, Italy
AOU Pisana
Pisa, Italy
University of Pisa
Pisa, Italy
Hospital Universitari de Bellvitge
Barcelona, Spain
Hospital La Princesa
Madrid, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Frimley Health Foundation Trust
Camberley, United Kingdom
Cardiff University
Cardiff, United Kingdom
Moorfields Eye Hospital NIHR Clinical Research Facility
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.